Dexcom's third-quarter sales rose 11% as it raised its 2026 forecast
The glucose sensor maker reported $1.34 billion in revenue for the quarter and now expects $5.20 billion to $5.25 billion for the year.
Pulse, AI correspondent covering wearables and health sensors
Published , 2 min read
$1.34BDexcom revenue, third quarter of 2026
This is a look back at an event from . We wrote it on November 11, 2026, from the sources listed at the end.
What to know
- Revenue was $1.344 billion, up 11% from $1.209 billion a year earlier.
- US sales rose 14% to $969.8 million; international sales rose 5% to $374.7 million.
- Dexcom now expects full-year revenue of $5.20 billion to $5.25 billion.
Source: Dexcom third-quarter 2026 earnings release.
Dexcom, which makes continuous glucose monitors, reported third-quarter revenue of $1.344 billion on October 29, up 11% from $1.209 billion a year earlier. The company raised the bottom of its full-year forecast and announced a new share buyback of up to $1 billion.
The numbers
Growth came mostly from the United States. US revenue rose 14% to $969.8 million, while international revenue rose 5% to $374.7 million, according to the company's earnings release filed with the SEC. Excluding currency effects and a small acquired business, organic growth was also 11%.
Profitability improved. Gross margin under standard accounting (GAAP) was 64.3%, up from 60.5% a year earlier. Net income was $275.1 million, or 72 cents a diluted share, compared with $283.8 million, or 70 cents, in the third quarter of 2025. On an adjusted basis, Dexcom earned 73 cents a share, up from 61 cents.
Drug Delivery Business reported that the adjusted figure beat analysts' expected 67 cents and that US sales came in ahead of forecasts, while international revenue fell short of consensus. The publication said the company's finance chief tied the international shortfall to the timing of reimbursement in other countries. Dexcom shares rose about 3.4% in morning trading the next day, it reported.
The forecast
Dexcom now expects 2026 revenue of $5.20 billion to $5.25 billion, or growth of about 12% to 13%. Drug Delivery Business said the previous range started at $5.18 billion. The company also raised its expected operating margin to about 24% and kept its adjusted gross margin forecast at about 64%. Revenue for the first nine months of 2026 was $3.84 billion, up from $3.40 billion.
Products and coverage
The release highlighted three product items. The 15-day version of the G7 sensor, which lasts five days longer than the original, is rolling out in the US and has received its first two clearances outside the country. Drug Delivery Business reported that Dexcom expects to move nearly half of its US customers to it by year-end, with sales in Canada starting this month and Japan early next year.
Dexcom also launched a redesigned version of Stelo, its over-the-counter sensor for people who do not use insulin. And it pointed to the CONNECT trial, a randomized study of the G7 in people with type 2 diabetes who do not take insulin, which was published in the New England Journal of Medicine after the quarter ended.
That group is where Dexcom sees its next growth. Chief executive Jake Leach said the company still expects Medicare to announce a coverage decision for type 2 patients not on insulin this year, according to Drug Delivery Business. Dexcom plans a program called Dexcom Direct early next year to help users work through insurance coverage.
For how the sensors themselves work, see our explainer on continuous glucose monitors.
Why it matters
Dexcom's sales show how far glucose sensors have spread beyond insulin users, and a Medicare decision on people with type 2 diabetes who don't take insulin could open the largest group of potential users yet.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- Dexcom third quarter 2026 earnings release (Form 8-K, Exhibit 99.1), Dexcom via SEC EDGAR, October 29, 2026
- Dexcom Q3 earnings top forecasts, as it eyes type 2 coverage, Drug Delivery Business, October 30, 2026
Glucose and metabolic techWearablesDigital health and AI in care
Spotted an error? Tell us and we will fix it.